AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$MDT

Medtronic (MDT) Sets 4.5939 Final Exchange Ratio in MiniMed Split-Off

Medtronic (MDT) announced a final exchange ratio of 4.5939 for the split-off of MiniMed Group. This detail finalizes the exchange mechanics for the previously disclosed separation. No closing date or distribution mechanics were provided.

Original reporting
tradingview.com
Published Oct 7, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medtronic (MDT) Sets 4.5939 Final Exchange Ratio in MiniMed Split-Off — source image
Source · tradingview.com
Decision brief

The 30-second read

$MDTNeutralMed
01

Why it matters

The disclosed exchange ratio finalizes the mechanics, allowing valuation of both entities and may trigger rebalancing by index funds.

02

Market read

Provides traders with the exact conversion rate needed to assess the split‑off's impact on MDT and MiniMed valuations.

03

What to watch

Potential tax implications for shareholders and the timing of the distribution could affect the net value received.

Relevance 7/10Novelty 7/10Timing: same‑day release

Background

Medtronic is executing a planned separation of its MiniMed diabetes business, previously announced but without final terms.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic disclosed the final 4.5939 exchange ratio for the MiniMed split‑off, a new detail that determines how shareholders will receive MiniMed shares.

Expected impact

likely modest pressure as the market prices in the split‑off mechanics

Evidence & confidence

First disclosure of the exchange ratio provides concrete terms for the spin‑off, prompting traders to adjust positions.

Market effects

Sector

May influence other medical‑device peers as they evaluate similar spin‑off strategies.

Regional

Limited to U.S. and European markets where Medtronic trades.

Global

Low global impact beyond the healthcare sector.

Counterpoint

What could challenge this read

Some investors may view the split‑off ratio as undervaluing MiniMed, presenting a buying opportunity for the spin‑off.

Key entities

  • Company
    Medtronic

    US‑listed medical‑device manufacturer (ticker MDT).

  • Company
    MiniMed Group, Inc.

    Spin‑off entity focused on diabetes management.

Read at source← All news

Also covered by

3 outlets

Related articles

OCT 7
$MDTHighAI 8/10

Medtronic Sets MiniMed Split-Off Exchange Ratio at 4.5939 Upper Limit

Medtronic (MDT) set the final exchange ratio for its split-off of MiniMed (MMED) at 4.5939 shares of MMED for each MDT share. The ratio is at the offer's upper limit, valuing MDT shares at 100% and MMED at 93% of their average prices. The offer expires October 9, 2026, and may be oversubscribed, with proration possible. The exchange is expected to be tax-free for U.S. federal income tax purposes.

securities.io2 min
OCT 7
$MDTHighAI 8/10

Medtronic sets final exchange ratio for MiniMed split-off

Medtronic (NYSE:MDT) set the final exchange ratio for its offer to swap shares for MiniMed (NASDAQ:MMED) stock at 4.5939. The company will exchange up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic may exchange additional shares without extending the offer. The exchange offer expires at midnight on Friday.

investing.com2 min
OCT 7
$MDTMed

Medtronic (MDT) Could Be 24% Undervalued As CPT Code Wins Support Growth

Medtronic (MDT) received permanent CPT codes for its Altaviva and Symplicity Spyral devices. Shares are down 7.52% in 1 month and 9.33% YTD, but up 26.12% over 3 years. Analysts estimate MDT is 24.5% undervalued with a fair value of $115.38 vs. last close at $87.09. Management hinted at higher growth aspirations, to be detailed in December.

simplywall.st2 min
OCT 6
$MDTMedAI 8/10

Medtronic: Presents New Nocturia Data for the AltavivaTM Device, Announces National Principal Investigator for the ENDURANCE Study

Medtronic presented 24-month data for its AltavivaTM device at the 47th AUGS Annual Scientific Meeting, showing sustained reductions in nightly nocturia episodes. The company also announced a partnership to raise awareness of pelvic floor disorders. Medtronic is a global leader in healthcare technology, with a diverse portfolio of medical devices.

marketscreener.com2 min